
Loading, please wait...

Loading, please wait...

Axillary lymph node dissection is a critical procedure for many breast cancer patients undergoing surgical treatment. However, this surgical intervention carries a significant lifetime risk of developing lymphedema. This condition, known as breast cancer-related lymphedema (BCRL), affects approximately 20-30% of patients. During a mastectomy, surgeons may perform the dissection through the primary mastectomy incision or a separate axillary incision. Historically, clinicians have debated whether a separate incision causes more lymphatic disruption, potentially increasing lymphedema rates.
A recent retrospective study by Wang J et al. analyzed 1,036 patients to determine if the incision site impacts BCRL outcomes. The researchers compared 483 patients who received a separate axillary incision to 553 patients who underwent dissection through the mastectomy incision. The results indicated that separate axillary incisions do not increase lymphedema rates. Specifically, the lymphedema rate was 29% for the separate incision group versus 30% for the mastectomy incision group. Moreover, the difference between these cohorts was not statistically significant, with a p-value of 0.77.
Multivariable logistical regression further supported these clinical findings. Specifically, the analysis showed that patients undergoing axillary lymph node dissection via a separate incision did not have significantly greater odds of developing swelling (OR 0.89). Consequently, surgeons can choose the incision site based on oncologic safety and technical accessibility rather than fear of lymphedema. Furthermore, the median time to lymphedema development was 15 months, suggesting that long-term monitoring is essential regardless of the incision type used. In addition, prioritizing the thoroughness of lymph node retrieval remains the most important factor for oncologic success.
No, research indicates that performing the dissection through a separate incision does not significantly increase the risk of lymphedema compared to using the mastectomy incision.
While the incision type is not a major factor, significant risk factors include a high body mass index (BMI), regional lymph node radiation, and the total number of lymph nodes removed during the procedure.
The median time to development is approximately 15 months, though it can occur at any time during a patient\'s life following axillary lymph node dissection.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
1. Wang J et al. Axillary Lymph Node Dissection Through a Separate Incision Does Not Increase Rates of Breast Cancer-Related Lymphedema. Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-026-19215-x. PMID: 41665789.
2. Lindqvist EK, et al. Risk factors for lymphedema after breast cancer treatment. Lymphatic Research and Biology. 2022.
3. National Cancer Institute. Lymphedema (PDQ®)–Health Professional Version. 2024.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study of 1,036 patients found that performing axillary lymph node dissection through a separate incision does not increase lymphedema risk....
8 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today